{"id":"W2948104235","doi":"10.1056/nejmoa1902226","title":"An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1112,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; Janssen Pharmaceuticals; National Center for Advancing Translational Sciences; Genentech; Dexcom; National Institutes of Health; Servier; Zafgen; MannKind Corporation; MacroGenics; Immune Tolerance Network; American Diabetes Association; Massachusetts Medical Society; Novo Nordisk; Intarcia Therapeutics; Juvenile Diabetes Research Foundation United Kingdom; Yale University; Esperion Therapeutics; GlaxoSmithKline; National Center for Research Resources; National Institute of Allergy and Infectious Diseases; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Pfizer; National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi","keywords":"Medicine; Diabetes mellitus; Placebo; Internal medicine; Hazard ratio; Type 2 diabetes; Type 1 diabetes; Randomization; Confidence interval; Insulin; Gastroenterology; Randomized controlled trial; Endocrinology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012844,0.0003590086,0.0007195831,0.0001681864,0.0004887406,0.0002967163,0.0002106646,0.0007848996,0.001400505],"category_scores_gemma":[0.002820675,0.0001978059,0.0004929366,0.0002170658,0.0002442053,0.000261896,0.000212407,0.0006611386,0.0001297288],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003979201,"about_ca_system_score_gemma":0.0003751734,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009595064,"about_ca_topic_score_gemma":0.001014353,"domain_scores_codex":[0.9995572,0.000282849,0.00002312242,0.00006422668,0.0000324258,0.00004017379],"domain_scores_gemma":[0.9991869,0.000372595,0.0002250418,0.00002656051,0.00003098378,0.0001578845],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5656092,0.008422537,0.228083,0.00183951,0.001465752,0.00194065,0.0006706484,0.001171739,0.0115545,0.0002844119,0.002001,0.1769571],"study_design_scores_gemma":[0.1711108,0.4152651,0.3739404,0.001195513,0.008064657,0.006787576,0.00125381,0.004150819,0.007479833,0.001680485,0.008959967,0.0001111359],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921575,0.006833055,0.0001227202,0.0002830909,0.00006958916,0.00003475328,0.00002383499,0.000008470422,0.0004671198],"genre_scores_gemma":[0.998569,0.0009889816,0.0001604899,0.0001214671,0.00004127956,0.00001951484,0.00001179622,6.2687e-7,0.0000867737],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001400505,"threshold_uncertainty_score":0.006792665,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008130474669345241,"score_gpt":0.2819474254084911,"score_spread":0.2738169507391459,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}